Oranje W A, Rondas-Colbers G J, Swennen G N, Wolffenbuttel B H
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands.
Neth J Med. 1998 Aug;53(2):61-8. doi: 10.1016/s0300-2977(98)00066-7.
Macrovascular disease is the leading cause of death in diabetes. The increased risk of atherosclerosis in diabetes may be partly explained by increased lipid peroxidation.
We assessed lipid peroxidation in subjects with type 2 diabetes with (n = 23) and without (n = 23) macrovascular complications versus healthy age-matched controls (n = 13). The diabetic groups were matched for glycemic control (mean HbA1c = 9%), and for age had similar known duration of diabetes.
Plasma TBARS were comparable between diabetic subjects with and without macrovascular complications (1.89 +/- 0.32 and 1.81 +/- 0.28 mumol/l) and elevated compared to healthy controls (1.64 +/- 0.26 mumol/l, p = 0.025). Ratios of IgG and IgM antibodies to oxidized vs. native LDL were comparable between diabetic subjects and controls, and also between diabetic subjects with or without macrovascular complications. The lag phase, an index of the resistance of LDL to oxidation, was significantly longer in diabetic patients with macrovascular complications (66 +/- 8 min) vs. those without macrovascular complications and controls (resp. 59 +/- 7 and 56 +/- 7 min, p < 0.05). An explanation may be the frequent use of drugs with possible antioxidant potential, e.g. beta-blocking agents, ACE-inhibitors and calcium entry blockers by these patients. Surprisingly, plasma vitamin E levels were higher in diabetic subjects.
We found no evidence of increased lipid peroxidation in diabetic subjects with macrovascular complications, but an increased resistance to oxidation in this group, probably due to an altered antioxidant status. The increased TBARS level in diabetic subjects contrasts with the other indices of lipid peroxidation and may be related to prevalent hyperglycemia and should therefore be interpreted cautiously.
大血管疾病是糖尿病患者的主要死因。糖尿病患者动脉粥样硬化风险增加的部分原因可能是脂质过氧化作用增强。
我们评估了2型糖尿病伴大血管并发症(n = 23)和不伴大血管并发症(n = 23)患者以及年龄匹配的健康对照者(n = 13)的脂质过氧化情况。糖尿病组在血糖控制方面(平均糖化血红蛋白 = 9%)相匹配,且年龄、已知糖尿病病程相似。
伴和不伴大血管并发症的糖尿病患者血浆硫代巴比妥酸反应物(TBARS)水平相当(分别为1.89±0.32和1.81±0.28μmol/L),但均高于健康对照者(1.64±0.26μmol/L,p = 0.025)。糖尿病患者与对照者之间,以及伴或不伴大血管并发症的糖尿病患者之间,氧化型与天然低密度脂蛋白(LDL)的IgG和IgM抗体比率相当。LDL氧化抗性指标——延滞期,在伴大血管并发症的糖尿病患者中(66±8分钟)显著长于不伴大血管并发症的糖尿病患者及对照者(分别为59±7和56±7分钟,p < 0.05)。一个可能的解释是这些患者频繁使用了具有潜在抗氧化作用的药物,如β受体阻滞剂、血管紧张素转换酶抑制剂和钙通道阻滞剂。令人惊讶的是,糖尿病患者血浆维生素E水平较高。
我们没有发现伴大血管并发症的糖尿病患者脂质过氧化增加的证据,但该组患者抗氧化能力增强,可能是由于抗氧化状态改变所致。糖尿病患者TBARS水平升高与脂质过氧化的其他指标形成对比,可能与普遍存在的高血糖有关,因此应谨慎解读。